User: TahirAmin Topic: IP
Category: drugs :: india
Last updated: Apr 20 2018 15:46 IST RSS 2.0
 
1 to 20 of 6,197    
Big opportunities in defence, mfg, pharma to boost India, UK investments: UKIBC 20.4.2018 General News
A huge potential exists in sectors including manufacturing, defence, pharmaceuticals and start-ups to boost investments between India and the UK, a report by the UK India Business Council (UKIBC) has said. "Exciting trends in digitisation, including the onset of 4-IR (industrial revolution), are creating new investment opportunities. The rise of smart cities, the potential of fintech, along with the start-up culture, has generated areas where investment potential is exponential but as yet largely untapped," the report said. It said that industry revolution would impact virtually all sectors of the economies of India and the UK; and growing usage of artificial intelligence, robotics, Internet of Things, blockchain, big data and 3D printing open new opportunities for collaborations and investment in both countries. Making a case for early negotiations for a free trade agreement, it said that the current business environment in both the countries is conducive for mutual investment ...
Also found in: [+]
Pharma formulators to invest in growing OTC market: Report 18.4.2018 General News
Indian pharmaceutical formulators are expected to continue to make investments in consumer healthcare, wellness products and traditional OTC product categories to grow domestic non-prescription business through organic and inorganic routes, a report said. These investments would be driven by the need to further diversify the domestic prescription business, India Ratings and Research (Ind-Ra) said in its report. According to Business Monitor International (BMI), India's non-prescription or OTC market contributes around 14.5 per cent to the total pharmaceutical sales and is expected to grow to USD 4.2 billion at a CAGR of 8.8 per cent over 2017-2022. The growth is likely to be driven by limited household affordability for frequent clinical visits, convenience of direct purchase and growing preference for self-medication for minor ailments, it said. Investments by Indian formulators are likely to be in consumer healthcare and wellness products, apart from the traditional ..
Also found in: [+]
Torrent Pharmaceuticals draws up plan to reduce dependence on US 18.4.2018 Business Standard: News Now
Company to draw 47% of revenue and 67% of Ebitda from Indian business by FY20
Also found in: [+]
Glenmark Pharmaceuticals gets final approval for Tacrolimus Ointment, 0.1% 18.4.2018 General News
From USFDA
Also found in: [+]
Children in polluted cities at increased risk of Alzheimer's, reveals study 14.4.2018 Business Standard: News Now
The findings indicated that Alzheimer's starts in early childhood
Also found in: [+]
U.S. wants patent form recall 14.4.2018 Hindu: Fitness
Submission on interpretation of a domestic patent law raises eyebrows
Also found in: [+]
Canadian pharmacy to be fined millions for illegal imports 13.4.2018 General News
An online pharmacy that bills itself as Canada's largest is expected to be fined USD 34 million today for importing counterfeit cancer drugs and other unapproved pharmaceuticals into the United States, a sentence that one advocacy group called too light for such a heinous crime. Canada Drugs has filled millions of prescriptions by offering itself as a safe alternative for patients to save money on expensive drugs, and its founder, Kristian Thorkelson, has been hailed as an industry pioneer for starting the company in 2001. But US prosecutors say Canada Drugs' business model is based entirely on illegally importing unapproved and misbranded drugs not just from Canada, but from all over the world. The company has made at least USD 78 million through illegal imports, including two that were counterfeit versions of the cancer drugs Avastin and Altuzan that had no active ingredient, prosecutors said. After more than two years of struggling to get the international company to appear in US ..
Also found in: [+]
Welcure Drugs & Pharmaceuticals to take up results 12.4.2018 General News
On 21 April 2018
Also found in: [+]
Milan Paleja to head Novartis operations in India 11.4.2018 General News
Drug firm Novartis India today said it has appointed Milan Paleja as Country President with immediate effect. Paleja, who succeeds Jawed Zia, will also head the company's pharmaceutical business in the country, Novartis India said in a statement. Prior to this, Paleja was Country President and Head Pharmaceuticals, Novartis Indonesia, where he pioneered innovative access models, turned around the business and laid the foundation for future growth, it said. Paleja is a graduate from Bombay University and holds a Cost Accountants degree from the Institute of Cost Accountants of India.
Also found in: [+]
Patents and protecting public health 9.4.2018 Hindu: Op-Ed
Seeking full disclosure on how patents are working locally through Form 27 will help promote innovation
Also found in: [+]
Pharma sector likely to report weak numbers in Q4 8.4.2018 General News
The troubled pharma sector is expected to report weak Q4FY18 numbers, with PAT likely to decline by 9 per cent (year-on-year) and appreciation in rupee may put pressure on realisations, industry analysts said. "We estimate the pharma sector to report weak Q4FY18 numbers - while revenue is likely to grow at 3 per cent y-o-y, PAT is expected to decline 9 per cent y-o-y. We expect US revenue to dip 2 per cent y-o-y in constant currency (cc) - five consecutive quarters of decline - led by sustained pricing pressure due to customer consolidation and rise in competition," Edelweiss research analyst Deepak Malik told PTI here. The rupee appreciation of 4 per cent y-o-y against the USD will put further pressure on realisations. However, this is likely to be partly offset by rupee depreciation against the Euro/Rand/Yen by 11 per cent, 6 per cent and 1 per cent y-o-y, Malik said. We forecast domestic sales to grow 11 per cent y-o-y on a low base, he said. While pricing controls keep the ...
Also found in: [+]
Bengal Chemicals Net at Rs 8.91cr, eyes Rs 200cr sale in FY'20 5.4.2018 General News
Bengal Chemicals & Pharmaceuticals (BCPL), a PSU under the Ministry of Chemicals and Fertilisers, has posted a net profit for the second successive fiscal in 2017-18, after suffering losses since 1953. The company clocked a net profit of Rs 8.91 crore in the last fiscal on a revenue base of Rs 80 crore. "BCPL registered net profit of Rs 8.91 crore in the last fiscal for the second year in a row. In the current fiscal, we are tagetting a net profit of Rs 15 crore and the revenue to touch Rs 100 crore," MD of BCPL P M Chandraiah said. The company is eyeing a turnover of Rs 200 crore by 2019-20, he told reporters here today. Chandraiah said that the government gave a package of Rs 450 crore in 2006 to modernise and revive the company. Saying that BCPL is totally debt-free now, he added that the company would gradually meet up the balance principal payment of Rs 16 crore due to the government by December 31, 2018. On paying up the accumulated interest on government ...
Also found in: [+]
MTaI suggests gradual rollout of public procurement guidelines 5.4.2018 General News
The Medical Technology Association of India (MTaI) today said the Department of Pharmaceuticals should prepare a road map for phased implementation of guidelines on public procurement of medical devices. The Department of Pharmaceuticals (DoP) had issued draft guidelines for implementation of public procurement of medical devices in March this year. As per DoP's draft guidelines, implants, hospital equipment and medical devices should have a minimum local content ranging from 25-50 per cent to qualify for public procurement. Given that India's medical devices regulatory regime is fairly new and its implementation is nascent, any preferential provisions for public procurement applied to all segments of devices will only limit patient access and forbid several kinds of medical technology that is not locally being produced, MTaI said in a statement. "In view of the above, we strongly urge the DoP to carve out a road map for a phased implementation of local content requirements in order ..
Also found in: [+]
True tech power comes from harvesting patents: ISRO, Cipla and Biocon show the way for future entrepreneurs 4.4.2018 Latest News India on Firstpost
Is there an entrepreneur out there who has the money and the audacity to gamble on a new future? India could do with some audacious private entrepreneurs.
Also found in: [+]
Glenmark Pharmaceuticals and Helsinn Group enter into an exclusive licensing agreement 4.4.2018 General News
AKYNZEO, an oral fixed combination of netupitant 300mg and palonosetron 0.5mg in capsule form, is used for prevention of chemotherapy-induced nausea and vomiting (CINV). The licensing agreement with Glenmark for AKYNZEO represents Helsinn's first such agreement in India. Glenmark will have exclusive marketing rights for AKYNZEO in India and Nepal.
Also found in: [+]
Glenmark, Helsinn Group tie up for CINV drug sale in India, Nepal 4.4.2018 General News
Glenmark Pharmaceuticals today said it has signed a licensing agreement with Swiss pharma player Helsinn Group to introduce 'Akynzeo' in India and Nepal, a drug that helps prevent chemo-related nausea and vomiting. The licensing agreement for Akynzeo represents Helsinn's first such agreement in India, the company said in a statement. The drug was developed by Helsinn and is currently marketed in European Union, the US, and other leading markets. Glenmark will have exclusive marketing rights for the drug in India and Nepal, it said, adding that the marketing approval has been received for Akynzeo from the Central Drugs Standard Control Organization (CDSCO). "Akynzeo will help Indian patients undergoing chemotherapy and struggling to manage CINV (Chemotherapy Induced Nausea and Vomiting) to address this issue in a much better manner," Glenmark PresidentIndia Formulations, Middle East and Africa Sujesh Vasudevan said. An oral fixed combination of netupitant 300mg and palonosetron 0.5mg ..
Also found in: [+]
'Pharma may see recovery with FY19 profit set to jump 20-22%' 3.4.2018 General News
After a bruising two years, the domestic pharmaceutical sector is set for a sharp turnaround in the new fiscal year with a 20-22 per cent growth in operating profit - the fastest pace since 2014, while revenue may grow at 9-11 per cent, according to a report. "The projected good run is premised on a decline in regulatory alerts for larger companies as well as a bigger pipeline of high-value drugs compared to the past two years. Operating income and profit will see a course reversal with a 20-22 per cent growth, while revenue may clip at 9-11 per cent," rating agency Crisil said in a report. This will be primarily on the back of strong growth in the overseas market, particularly in the regulated markets of the US and the EU, while the domestic market will continue its healthy growth in the past years, it said. It can be noted that although exports account for only 50 per cent of revenue for the domestic pharma industry, its contribution at the operating profit is higher ..
Also found in: [+]
Corona Remedies acquires two brands from Abbott 2.4.2018 General News
City-based pharma firm Corona Remedies today announced the acquisition of Obimet and Thyrocab brands, comprising of 14 product line extensions, from Abbott India. Both these brands are popular prescription drugs to manage diabetes and hyperthyroidism, Tejas Kothari, Head-Strategy at Corona said. "This is the second brand acquisition by the company in the past year. Both these brands acquired by us are expected to garner a sales revenue of around Rs 25 crore in the first year of integration," Kothari told media persons here today while making the announcement. In addition to the acquisitions, the company has also announced to set up its second manufacturing facility at Bavla village near Ahmedabad. At present, the company is having its manufacturing facility in Himachal Pradesh. "Our existing plant in Himachal Pradesh is having a manufacturing capacity of 100 crore tablets, 6 crore capsules and one crore liquid bottles per annum," said Vijay Charlu, vice president of ...
Also found in: [+]
Analysis: In broad healthcare bets, small stocks favoured over large 27.3.2018 General News
NEW YORK (Reuters) - When it comes to investing in the U.S. healthcare sector, it has paid off big to bet on smaller stocks.
Also found in: [+]
GSK backs out of $20 bn bidding race for Pfizer's consumer health-care unit 23.3.2018 Latest News
Pfizer is the world's fifth-largest player in consumer health with 2.5 percent of a market bolstered by ageing populations and growing interest in health and wellness
Also found in: [+]
1 to 20 of 6,197